BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220509
DTEND;VALUE=DATE:20220511
DTSTAMP:20260515T215236
CREATED:20220124T115213Z
LAST-MODIFIED:20220124T115300Z
UID:32925-1652054400-1652227199@www.pharmajournalist.com
SUMMARY:SMi’s 6th Annual Highly Potent Active Pharmaceutical Ingredients
DESCRIPTION:SMi’s 6th Annual Highly Potent Active Pharmaceutical Ingredients \nConference: 9 – 10 May 2022\nLondon\, UK\nWebsite: www.highlypotentapi.com/WLPJ \nChaired by Justin Mason-Home\, Owner\, Director\, HPAPI Project Services Limited  \nEnsuring Risk-Based\, Safety-Driven\, High-Quality Operation \nSMi is proud to present its 6th Annual Highly Potent Active Pharmaceutical Ingredients\, taking place on the 9 – 10 May 2022. \nThe Global High Potency API/HPAPI Market is projected to reach 37 billion USD by 2027\, growing at an ever-increasing CAGR of 8.43%. The expanding production of high potency APIs\, along with the increase in associated toxicities\, are driving requirements for more effective containment solutions and much-needed guidelines to ensure worker safety. \nSMi Group are delighted to announce the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference will be taking place on 9th – 10th May 2022 in London\, UK. The conference will encompass the critical topics including risk assessment\, occupational toxicology\, engineering controls for containment\, facility design\, and the impact of pharmaceutical manufacture on the environment. \nBenefits of Attending the HPAPI Conference: \n\nDissect comprehensive hazard assessment and occupational exposure limit determination\nEvaluate the increasing trend toward more potent therapies and the consequences of the changing face of pharma\nAssess engineering containment controls\, from isolators and barriers to fully automated lines\nExplore the employment of cleaning validation\, organisational controls\, and facility as key measure to tackle cross contamination\n\nThis two-day conference offers you peer-to-peer networking with industry experts including heads and directors of EHS\, Occupational Hygiene\, Quality Assurance and more. Expand your community and explore the latest developments in the industry at this two-day event\, including key regulatory updates\, and leading case studies from leading pharmaceutical and biotechnology companies. \nEarly Birds: \n\nRegister by 31st January to save £400\nRegister by 28th February to save £200\nRegister by 31st March to save £100\n\nEvent Hashtag: #SMiHPAPi
URL:https://www.pharmajournalist.com/event/smis-6th-annual-highly-potent-active-pharmaceutical-ingredients/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SMi Events":MAILTO:ngaloria@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220509
DTEND;VALUE=DATE:20220512
DTSTAMP:20260515T215236
CREATED:20220222T100531Z
LAST-MODIFIED:20220222T100531Z
UID:33327-1652054400-1652313599@www.pharmajournalist.com
SUMMARY:LEAP HR: Life Sciences West 2022
DESCRIPTION:LEAP HR: Life Sciences West is your best opportunity to hear how scaling life sciences organizations are implementing the experimental people strategies required to drive innovation and growth whilst operating in a tight talent market. \nStep inside 30+ case studies of the radical\, future-focused HR thinking that will empower you to transform your impact and turbocharge scale and innovation in biotech\, pharma and medical devices organizations. \nGain access to the HR innovation that is truly making a difference to employees\, patients and customers – and leave with a brand-new playbook for the people function to thrive in the fast-paced operating environments of life sciences organizations on the West Coast and surrounding areas. \nWith a world-class speaker faculty from leading life sciences organizations such as: Atara Biotherapeutics\, Gilead Sciences\, BridgeBio\, Assembly Biosciences\, Revolution Medicines\, 10X Genomics and many more. \nWhether your business is rapidly growing\, undergoing serious transition or quickly evolving\, LEAP HR: Life Sciences West is your opportunity to plug into a ready-made network of peers who have already solved the talent challenges you’re facing in a candidate-led talent market on the tech-hub West Coast and surrounding areas. \nTo know more visit: https://bit.ly/3h3w3Nt
URL:https://www.pharmajournalist.com/event/leap-hr-life-sciences-west-2022/
LOCATION:Marriott La Jolla\, 4240 La Jolla Village Dr\, La Jolla\, CA\, 92037\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220510
DTEND;VALUE=DATE:20220513
DTSTAMP:20260515T215236
CREATED:20220105T163123Z
LAST-MODIFIED:20220106T100246Z
UID:32667-1652140800-1652399999@www.pharmajournalist.com
SUMMARY:Adenosine-Pathway Targeted Cancer Immunotherapy Summit
DESCRIPTION:Adenosine-pathway therapies have produced a plethora of promising clinical trial data that is being met with refreshed excitement\, enthusiasm\, and R&D investment for adenosine-pathway targets. \nWith reinvigorated confidence in the field\, join fellow industry and academic thought leaders at the inaugural Adenosine-Pathway Targeted Cancer Immunotherapy Summit. This is the only comprehensive forum dedicated to optimizing efficacy of adenosine-pathway targeted drugs\, overcoming challenges of resistance and immunosuppression and supercharging therapeutics to patients in need. \nFrom analyzing the latest developments in understanding adenosine signaling in the TME\, to rationalizing drug combinations that enhance patient responses\, and exploring tools that quantify adenosine to select patients\, this is the one-stop-shop event for all things adenosine-pathway. \nHarness cutting-edge insights across 3 days of exclusive content from industry heavyweights including Astrazeneca\, Takeda\, Corvus Pharmaceuticals\, iTeos Pharmaceuticals\, Domain Therapeutics and more. Leave this definitive conference equipped with novel ideas\, actionable lessons learned and new connections enabling you to progress your adenosine-pathway targeted cancer immunotherapies to the clinic. \nTo know more visit: https://ter.li/q8tgbz
URL:https://www.pharmajournalist.com/event/adenosine-pathway-targeted-cancer-immunotherapy-summit/
LOCATION:Omni Parker House\, 60 School St\, Boston\, MA\, 02108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220510
DTEND;VALUE=DATE:20220513
DTSTAMP:20260515T215236
CREATED:20220207T093750Z
LAST-MODIFIED:20220207T093750Z
UID:33162-1652140800-1652399999@www.pharmajournalist.com
SUMMARY:7th Annual 3D Tissue Models Summit 2022
DESCRIPTION:Integrate Advanced 3D Models with Scalability & Predictability to Supercharge Your Modeling Toolbox & Enhance Clinical Confidence \nFollowing the FDA’s announcement of ‘Alternative Methods Working Group’ in the summer\, 2021\, Roche’s newly opened pRED Innovation Center in Basel\, and exciting data from Recce Pharma’s anti-infective candidate using organoids\, the 7th Annual 3D Tissue Models Summit will return to Boston in May 2022 to reunite the community of drug discovery and development experts. This is the definitive meeting for drug developers to explore and integrate complex 3D models featuring 30+ real-life case studies across 2 dedicated tracks and their lessons learned. \nJoin us in May to stay ahead of the curve and through 30+ real-life case studies\, you will learn and meet trailblazers in 3D models to revolutionize your drug discovery and development protocols\, giving you greater confidence in clinical relevancy and accelerating novel treatments to patients in a safe and affordable manner! \nTo know more visit: https://ter.li/oly672
URL:https://www.pharmajournalist.com/event/7th-annual-3d-tissue-models-summit-2022/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220510
DTEND;VALUE=DATE:20220513
DTSTAMP:20260515T215236
CREATED:20220216T112754Z
LAST-MODIFIED:20220216T112754Z
UID:33261-1652140800-1652399999@www.pharmajournalist.com
SUMMARY:3rd Manufacturing Engineering & Facility Management in Pharma Summit
DESCRIPTION:Following innovative technological breakthroughs and the FDA’s Emerging Technology Program\, the pharmaceutical industry is experiencing a renaissance period with an unprecedented level of investments in new builds and next-generation technology to support novel pipeline progression. \nThe ability to commission a modern\, flexible\, compliant facility on time and a budget have never been so critical to drug developers and patients worldwide. \nThe 3rd Manufacturing Engineering & Facility Management in Pharma Summit is the industry’s first definitive discussion and networking forum designed to reunite leaders in the manufacturing and facilities fields in person after two years to share scientific breakthroughs and address challenges the industry is facing. With the pharmaceutical industry entering Pharma 4.0\, technology advances and facilities designs must adapt to a digital\, remote world to enhance tomorrow’s CGT pipeline. \nDesigned alongside the likes of Bayer\, AstraZeneca\, and Catalent\, this industry-focused forum allows you to discuss novel cutting-edge technologies\, the latest approaches of engineering modular\, flexible facilities and address the supply chain crisis. \nWith 22+ hours of content\, 3 interactive workshops\, and over 2 hours of networking with key industry leaders\, this comprehensive forum will uniquely combine leaders in the manufacturing\, engineering\, and facilities fields in one setting to share lessons learned\, case studies\, and advancements in the field. \nJoin 80+ of your peers and be part of this unique opportunity to engage in cross-industry discussions and presentations from 20+ expert speakers on sharing technology innovations that are transforming the manufacturing field\, maximizing productivity and capital efficiency through excellent engineering and facility management\, and collaborating with stakeholders to ensure on-time\, on-budget commissioning\, and validation. \nJoin us this May to maximize your facility flexibility\, asset lifespan\, productivity & compliance through excellent engineering\, robust validation & technology adoption! \nTo know more visit: https://ter.li/qe5ezy
URL:https://www.pharmajournalist.com/event/3rd-manufacturing-engineering-facility-management-in-pharma-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220511
DTEND;VALUE=DATE:20220513
DTSTAMP:20260515T215236
CREATED:20220207T100435Z
LAST-MODIFIED:20220207T100435Z
UID:33172-1652227200-1652399999@www.pharmajournalist.com
SUMMARY:Injectable Drug Delivery Conference 2022
DESCRIPTION:SMi Group Introduces the 4th Annual…  \nInjectable Drug Delivery Conference 2022 \n11th May to 12th May 2022\, \nLondon\, United Kingdom \nwww.injectable-drug-delivery.com/ \nInnovations in Formulation and Device Design for Enhanced Subcutaneous Delivery \nAs Part of Europe’s leading Injectable conference series\, we will assess innovations in drug product formulation and biologics\, new technologies in device design and the use of long-release injectable compounds. \nThere is a rising demand for vaccines\, insulin\, and many modern medicines used to treat cancer and other chronic diseases. As biologics are mainly administered through the injectable route\, the significant growth in the biologics market is expected to drive the injectable drug delivery and prefilled syringe market in the coming years. The injectable drug delivery market is expected to rise at a compound annual growth rate of 12.9% reaching £915 billion by 2027. \nThis year’s event will highlight the significance of sustainability within the injectable drug delivery industry\, whilst also providing regulatory insight on the changes that have occurred. There will be an additional focus on the impact that covid has had on the success within this industry over the past year. The conference will also highlight successes within the industry and the formulation challenges of long-lasting\, highly viscous and high-volume drug delivery. \nThe benefits of attending: \n\nDiscover the new technologies and latest injectable devices being used within the industry\nDevelop your understanding of high-volume and long-acting injectable compounds\nExplore the sustainable possibilities that can be adapted within the industry for a green future\nDelve into the world of biologics and biosimilars and what these mean for the injectable drug market\nNetwork with key industry leaders and discover the leading companies within the injectables space\n\nWho should attend: \nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers\, Scientists\, Researchers of: \n\nAutoinjectors\nWearables\nDevice Engineering\nHuman Factors\nCMC\nInjectables\nSterile Manufacturing\nPackaging\nRegulatory Affairs\n\nFeatured Speakers: \n\nAlexander Zuern\, Device testing manager\, Novartis International AG\nAndrew Warrington\, Project Leader & Patient Advocate\, Novartis\nBenjamin Werner\, Scientist\, Boehringer Ingelheim Pharma GmbH & Co. KG\nBjorg K Hunter\, Regulatory Manager\, Devices\, GSK\nBlake Green\, Senior Manager Regulatory Affairs\, Amgen\nCamille Dagallier\, Formulation and Drug Process Development Senior Scientist\, Sanofi\nChristopher Muenzer\, Senior Device Technology Manager\, Novartis\nJoel Richard\, Head of Technical & Pharmaceutical Operations\, MedinCell\nMark Palmer\, Scientific Leader\, Biopharm Device Engineering\, GSK\nRebecca Moses\, Director\, Core Human Factors Inc.\nRupal Nguyen\, Principal Engineer\, Allergan\nStefania Ragone\, Pharmaceutical Assessor\, Medicines & Healthcare Products Regulatory Agency (MHRA)\nTina Arien\, Principal Scientist\, Janssen Pharmaceutica\nVikas Jaitely\, Director\, Global Regulatory Affairs Transitional Medicine and Devices\, Merck\n\nPast attendees have included \nAdvanz Pharma; Amgen; AstraZeneca; BD – Becton Dickinson; Bd Medical-Pharmaceutical Systems; BD Technologies and Innovation; Becton Dickinson; Boehringer Ingelheim GmbH & Co. KG; Boehringer Ingelheim Pharma GmbH & Co. KG; BSI Group; Chugai Pharmaceutical CO. LTD.; Congenius; Core Human Factors; F Hoffmann -La Roche Inc; GlaxoSmithKline; Glenmark Pharmaceuticals Inc.; GSK; Haselmeierá; Haughton Design Ltd; Ipsen Biopharm Limited; Janssen Pharmaceutica; Janssen Pharmaceutica NV; Legacy Allergan/AbbVie; LEO Pharma A/S; MedinCell; Merck; Merck Connected Health & Devices; MHRA; Micropore Technologies Ltd; Novartis / DD&C; Novartis International AG; Novo Nordisk Pharma; Owen Mumford; Pfizer UK Limited; Raumedic AG; Roche; SABIC; Sabic SHPP; Sandoz – A Novartis Company; Sanofi; Sanofi SWI; Team Consulting; Teva Pharamceuticals; UCB; Vetter Pharma-Fertigung GmbH & Co. KG; Zealand Pharma A/S \nAdditional Contact Info: \nT: +44 (0)20 7827 6088 \nE: rjones@smi-online.co.uk \nLinkedIn: @SMi Pharma \nTwitter: @SMiPharm #SMiInjectables
URL:https://www.pharmajournalist.com/event/injectable-drug-delivery-conference-2022/
LOCATION:London\, United Kingdom
ORGANIZER;CN="SMi Events":MAILTO:rjones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220517
DTEND;VALUE=DATE:20220520
DTSTAMP:20260515T215236
CREATED:20220106T133126Z
LAST-MODIFIED:20220106T133728Z
UID:32678-1652745600-1653004799@www.pharmajournalist.com
SUMMARY:4th Microbiome Movement - Maternal & Infant Health Summit 2022
DESCRIPTION:The 4th Microbiome Movement - Maternal & Infant Health Summit is returning\, in person\, on May 17-19\, 2022 with the goal of uniting expert industry and academic minds to tackle the biggest challenges in the understanding\, targeting and treatment creation for the maternal and infant microbiome. \nThis summit is the only place where you will find such a collaborative and engaged group of speakers and attendees with a diverse group of backgrounds in academia\, drug discovery\, nutritional product creation and clinical health care – you can be sure to hear a wide range of opinions and perspectives. \nEnsure you do not miss out on the latest and greatest work in fields relating to the microbiome such as maternal health\, the vaginal microbiome\, harnessing the microbiome for preventative treatment\, breastmilk\, pre-term birth and infant allergic/metabolic disease. \nTo know more visit: https://ter.li/81ntsl
URL:https://www.pharmajournalist.com/event/4th-microbiome-movement-maternal-infant-health-summit-2022/
LOCATION:DoubleTree by Hilton Hotel Boston – Bedford Glen\, 44 Middlesex Turnpike\, Bedford\, MA\, 01730\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@microbiome-movement.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220517
DTEND;VALUE=DATE:20220520
DTSTAMP:20260515T215236
CREATED:20220114T102623Z
LAST-MODIFIED:20220209T111249Z
UID:32776-1652745600-1653004799@www.pharmajournalist.com
SUMMARY:Pharma Clinical 2022
DESCRIPTION:The pandemic response has accelerated technology adoption in clinical trials\, but we have neglected patient needs by failing to develop co-created\, data-driven\, standardised and accountable trial designs.  \nIn the face of rethinking clinical strategy\, our mission is clear: it’s time to develop a better system. We must establish new industry-wide benchmarks now\, leverage recent digital innovations\, and ensure permanent cultural change toward patient- centric trials. If we do not act immediately\, we risk losing this opportunity to rebuild patient trust.    \nThis is why we are bringing together the world’s clinical leadership at Reuters Events: Pharma Clinical 2022 (May 17-19\, Virtual). We aim to define the new standards in digital and patient innovation for clinical transformation. Join 500 + clinical innovators and 40 + expert speakers to create an accountable clinical ecosystem where patient diversity\, centricity and empowerment aren’t just slogans – they are core principles.    \nTo know more visit: https://bit.ly/3npeUkP
URL:https://www.pharmajournalist.com/event/pharma-clinical-2022/
LOCATION:Virtual
ORGANIZER;CN="Reuters Events":MAILTO:usmaan.khan@thomsonreuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220517
DTEND;VALUE=DATE:20220520
DTSTAMP:20260515T215236
CREATED:20220120T182955Z
LAST-MODIFIED:20220120T182955Z
UID:32838-1652745600-1653004799@www.pharmajournalist.com
SUMMARY:4th Treg Directed Therapies Summit
DESCRIPTION:As Biopharma turn their focus to autoimmune drug development\, there has been an explosion of interest and investment into Treg directed therapies. Promising proof-of-concept data and early clinical read outs have fueled further hype\, and the industry now looks to demonstrate efficacy. \nThe 4th Treg Directed Therapies Summit returns to Boston this May\, bigger and better than ever before\, boasting 2 tracks of unparalleled content to cater to cell-based\, and non-cell-based experts alike. This is the only industry-focused meeting designed to bridge the gap between early discovery through clinical development of cell-based and non cell-based Treg directed therapies to provide efficacious treatments for patients globally. \nWith 3 days of unrivalled content spanning the fundamental biology of Tregs\, optimizing early drug development\, and streamlining clinical development\, join with your team to: \n\nOptimize stable expansion of Tregs to maintain function to elicit durable responses\nDecode Treg interactions to optimize the mechanism of actions and inform biomarker development\nRationalize activation\, formulation & delivery strategy to induce antigen specific tolerance\nSupercharge CMC strategy to drive the modulation of antigen-specific responses to yield maximum clinical efficacy\n\n200+ senior level drug developers will be uniting in May to chase the holy grail of Treg-directed therapies. Don’t miss your chance to network with the avant-garde to inform your Treg pipeline and capitalize on the shared knowledge of this collaborative community. \nTo know more visit: https://ter.li/fhrzm3
URL:https://www.pharmajournalist.com/event/4th-treg-directed-therapies-summit/
LOCATION:Embassy Suites by Hilton\, Boston Logan Airport 207 Porter St\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220517
DTEND;VALUE=DATE:20220520
DTSTAMP:20260515T215236
CREATED:20220201T115834Z
LAST-MODIFIED:20220201T115918Z
UID:33088-1652745600-1653004799@www.pharmajournalist.com
SUMMARY:Medical Device Software Development Summit 2022
DESCRIPTION:Bringing together a senior audience of cutting-edge device manufacturers\, and featuring a unique program focused on real-life use cases\, the 2022 Medical Device Software Development Summit offers you a toolkit for designing compliant\, innovative\, and secure medical device software\, enabling you to move one step ahead of emerging trends. \nSo whether you’re a part of a regulatory\, quality\, or technical team\, join the Medical Device Software Development Summit to meet like-minded peers who are pioneering new technologies and methodologies to develop innovative medical device software\, ultimately bringing value to patients. \n5 key topics at Medical Device Software Development Summit \n\nNavigate Regulations when Behind Innovation\nContinue to push the boundaries of innovation with AI-enabled medical devices\nUnderstand and implement agile software development methodologies\nImplement risk analysis into the software development lifecycle\nFocus your attention on device security to avoid breaches\n\nTo find out how you and your team can get involved download your free event guide or get in touch.
URL:https://www.pharmajournalist.com/event/medical-device-software-development-summit-2022/
LOCATION:DoubleTree by Hilton Hotel Boston\, North Shore\, 50 Ferncroft Rd\, Danvers\, MA\, 01923\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:monica.mojumder-chan@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220524
DTEND;VALUE=DATE:20220526
DTSTAMP:20260515T215236
CREATED:20220105T113225Z
LAST-MODIFIED:20220105T113225Z
UID:32657-1653350400-1653523199@www.pharmajournalist.com
SUMMARY:Customer Engagement Europe 2022
DESCRIPTION:Deliver enduring behavioral change with agile\, personalized engagement  \nPrecise\, Personalized and Proactive- the future of customer engagement is a digitally enabled\, hybrid omnichannel strategy.   \nHeard that all before?     \nFrom measuring clicks to measuring behaviour change\, the way we think about customer preference has forever been changed. Across marketing\, commercial\, and medical\, the skills we need to deliver on changing HCP expectations are aligning. Now is the time to do the same for our strategy.   \nReuters Events Pharma: Customer Engagement Europe 2022 (London\, May 24-25) is the only pharma event bringing together functions to drive the future of agile engagement. Join us to deliver a hybrid\, insight driven\, modularized model that incorporates iterative insights\, delves deeper into data\, empowers our field forces with digital empathy\, prioritizes innovation\, and equips our teams for industry leadership.   \nTo know more visit: https://events.reutersevents.com/pharma/customer-engagement-europe
URL:https://www.pharmajournalist.com/event/customer-engagement-europe-2022/
LOCATION:Hilton Tower Bridge\, London 5 More London Riverside\, Tooley St\, London\, SE1 2BY\, United Kingdom
ORGANIZER;CN="Reuters Events":MAILTO:saskia.burbach@thomsonreuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220524
DTEND;VALUE=DATE:20220526
DTSTAMP:20260515T215236
CREATED:20220117T091118Z
LAST-MODIFIED:20220117T091118Z
UID:32827-1653350400-1653523199@www.pharmajournalist.com
SUMMARY:Customer Engagement Europe 2022
DESCRIPTION:Precise\, Personalized and Proactive- the future of customer engagement is a digitally enabled\, hybrid omnichannel strategy. \nHeard that all before? \n \nFrom measuring clicks to measuring behaviour change\, the way we think about customer preference has forever been changed. Across marketing\, commercial\, and medical\, the skills we need to deliver on changing HCP expectations are aligning. Now is the time to do the same for our strategy.   \nReuters Events Pharma: Customer Engagement Europe 2022 (London\, May 24-25) is the only pharma event bringing together functions to drive the future of agile engagement. Join us to deliver a hybrid\, insight driven\, modularized model that incorporates iterative insights\, delves deeper into data\, empowers our field forces with digital empathy\, prioritizes innovation\, and equips our teams for industry leadership.   \nTo know more visit: https://bit.ly/3qz6d9B
URL:https://www.pharmajournalist.com/event/customer-engagement-europe-2022-2/
LOCATION:Hilton Tower Bridge\, London 5 More London Riverside\, Tooley St\, London\, SE1 2BY\, United Kingdom
ORGANIZER;CN="Reuters Events":MAILTO:saskia.burbach@thomsonreuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220524
DTEND;VALUE=DATE:20220527
DTSTAMP:20260515T215236
CREATED:20220125T090934Z
LAST-MODIFIED:20220125T114614Z
UID:32936-1653350400-1653609599@www.pharmajournalist.com
SUMMARY:Next Generation RNA Therapeutics Summit
DESCRIPTION:With novel RNA-based modalities having seen extraordinary development in the last 18 months\, there has never been a more important time for the RNA community to unite\, share learnings and accelerate the field towards successful proof of concept and effective therapeutic development. \nStay ahead of the curve with novel RNA therapeutics and vaccines that offer exceptional stability and durability whilst addressing key delivery\, pharmacology and scalability challenges to successfully translate safe and effective next generation RNA therapeutics into the clinic. \nThe Next Generation RNA Therapeutics Summit is the only meeting to deep dive into the specific challenges and opportunities associated with novel RNA modalities\, welcoming cutting-edge biotech giants such as Pfizer\, BioNTech\, Moderna Therapeutics and Replicate Bioscience to share unmissable insights on circular RNA\, tRNA and self-amplifying RNA therapeutics and vaccines. \nJoin 80+ thought leaders under one roof as they set the scene for next generation RNA therapeutics. This unique group of Directors\, Heads and VPs of RNA Therapeutics\, Chemistry\, Delivery and New Therapeutics will unite at this must-attend event for the RNA community. Don’t miss out! \nTo find out more\, visit: https://ter.li/0ei6ql
URL:https://www.pharmajournalist.com/event/next-generation-rna-therapeutics-summit/
LOCATION:Omni Parker House\, 60 School St\, Boston\, MA\, 02108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220524
DTEND;VALUE=DATE:20220527
DTSTAMP:20260515T215236
CREATED:20220207T101226Z
LAST-MODIFIED:20220207T101226Z
UID:33175-1653350400-1653609599@www.pharmajournalist.com
SUMMARY:4th Annual Cell Engager Summit
DESCRIPTION:4th Annual Cell Engager Summit  May 24-26\, 2022 | Boston\, MA \n\nThe 4th Annual Cell Engager Summit returns to bring you the latest on effectively targeting lymphocyte-restricted tumor-associated antigens to treat hematological malignancies\, including CD19\, CD20\, BCMA\, CD33\, and CD123. \n \nThis must-attend meeting will provide a comprehensive understanding of the development of multi-specific cell engaging therapeutics in liquid and solid tumor indications\, with the goal of bringing early-stage innovation to the clinic. \nLearn all there is to know about the immune cell engager landscape\, including clinical achievements\, potential response predictors\, and novel immune cell-based engager therapeutic discoveries. \nYou will leave this meeting with key steps to improving safety and efficacy in the solid tumor microenvironment through lower CRS\, greater dose\, and lower TMDD by targeting tumor antigens such as HER2 and EGFR\, and modifying co-stimulatory receptors (for example CD137/4-1BB\, CD28). \nEnsure your Cell Engager program reaches full clinical potential through learning from the pioneers of immunotherapy. \nTo know more visit: https://ter.li/d3i1x0
URL:https://www.pharmajournalist.com/event/4th-annual-cell-engager-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220524
DTEND;VALUE=DATE:20220527
DTSTAMP:20260515T215236
CREATED:20220405T114748Z
LAST-MODIFIED:20220406T094813Z
UID:33731-1653350400-1653609599@www.pharmajournalist.com
SUMMARY:Hippo Pathway Targeted Drug Development Summit
DESCRIPTION:It has long been understood that the Hippo pathway plays a critical role in the development of a wide range of diseases. Although once seen as an elusive pathway\, emerging novel data and research is forging a wider and more developed mechanistic understanding of it. New avenues have been opened to evolve the landscape of targetable nodes and therapeutic interventions\, from small molecule approaches to novel modalities targeting the TEAD transcription complex. \nWith the clear therapeutic potential of this highly attractive and targetable pathway\, investment\, collaboration\, and interest has flooded in through biopharma and academia – and what was once an unexploited space is now seeing an abundance of promising therapeutic interventions. \nThe inaugural Hippo Pathway Targeted Drug Development Summit has been established as the first and only industry dedicated forum focused on accelerating the mechanistic understanding and potential of the Hippo signaling pathway to enhance the discovery\, translation\, and clinical development of safe and effective drugs in oncology\, regenerative medicine and beyond. \nUniting the leading minds of large pharma\, biotech and academia\, this unrivalled conference will showcase the pioneering discoveries\, critical novel findings and promising clinical candidates drugging YAP\, TAZ & TEAD transcription factors and other high-value targets within the Hippo pathway. With Keynote sessions from Ikena Oncology\, Spring Works Therapeutics\, Cedilla and Vivace Therapeutics\, this is a unique opportunity to hear first-hand the development of novel YAP/TAZ-TEAD antagonists\, from discovery to the clinic. \nOver 80 key stakeholders from BridgeBio\, Cancer Research UK\, AstraZeneca\, Orion Pharma\, Faze Medicines\, Inventiva\, Zentalis Pharmaceuticals\, Basilea Pharmaceuticals and many more have already confirmed their places as the industry continues to unlock critical pieces of the puzzle in the understanding and exploitation of this signaling pathway. \nTogether\, we will unite to learn\, debate\, and discuss; leverage the therapeutic opportunity of this pathway; and critically address the huge unmet clinical need. \nTo know more visit: https://ter.li/4tdp3b
URL:https://www.pharmajournalist.com/event/hippo-pathway-targeted-drug-development-summit/
LOCATION:DoubleTree Suites by Hilton Hotel Boston\, 400 Soldiers Field Road\, Cambridge\, Boston\, MA\, 02134\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220525
DTEND;VALUE=DATE:20220528
DTSTAMP:20260515T215236
CREATED:20220126T092108Z
LAST-MODIFIED:20220126T092108Z
UID:32969-1653436800-1653695999@www.pharmajournalist.com
SUMMARY:ADC Analytical Development Summit
DESCRIPTION:As ADCs continue to see clinical success\, and as drug design becomes more complex\, regulatory scrutiny to ensure product quality is increasing. The trailblazing ADC Analytical Development Summit is the first and only industry focused meeting dedicated to addressing the unique challenges faced by analytical\, CMC\, QC\, process development and protein characterization experts working on ADCs. \nCovering the end-to-end development and application of analytical technologies in a phase-dependent manner\, this novel meeting will focus on enhancing ADC characterization\, understanding drug potency and demonstrating homogeneity to support regulatory requirements. \nWith the sharing of unique insights into novel method development\, CQAs\, bioassays\, DAR quantification and distribution\, and platform approaches\, this is your unmissable opportunity to get up to speed with this rapidly growing field and to support safe\, consistent and high quality ADC development. \nThrough a series of in-depth case studies\, interactive panel discussions and roundtables\, informative and enriching workshops\, and networking with likeminded individuals pioneering analytical development\, you’ll be equipped to advance your understanding of the safety\, identity\, potency\, purity and quality of your ADC. \nTo know more visit: https://ter.li/0ay4ao
URL:https://www.pharmajournalist.com/event/adc-analytical-development-summit/
LOCATION:Hyatt Regency Boston Cambridge\, 575 Memorial Drive\, Cambridge\, MA\, 02139\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220530
DTEND;VALUE=DATE:20220602
DTSTAMP:20260515T215236
CREATED:20220303T094518Z
LAST-MODIFIED:20220303T094518Z
UID:33420-1653868800-1654127999@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy Analytical Development Europe
DESCRIPTION:Uncover the Robust Analytical Methods to Guarantee Safe\, High Quality\, Consistent & Efficacious Gene Therapy Products \nIn the context of unprecedented gene therapy investment and clinical progress\, with mounting regulatory scrutiny\, Gene Therapy Analytical Development Europe will unite innovative biotech and pharma organisations to develop robust analytical tools to guarantee the consistency\, quality\, and safety of gene therapy products. \nWhether you’re looking for specific characterisation\, potency or infectivity approaches to improve your current analytical toolbox or if you’re seeking to understand how gene therapy analytics differ from other biologics you’ve worked on in the past\, this focused\, technical event will provide insights specifically on the unique analytical challenges posed by gene therapy vectors\, delivered by ‘boots on the ground’ scientists grappling with these challenges first-hand. \nJoin 150+ analytical pioneers to discover the realities of working with tools like dPCR\, AUC and HPLC\, as well as how and where these tools can be most effective in process development\, and what the European regulators expect in order to grant approval. Whether you’re working with AAV or lentiviral vectors\, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development. \nTo know more visit: https://ter.li/04rwmv
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-analytical-development-europe/
LOCATION:Victoria Park Plaza Hotel\, 239 Vauxhall Bridge Road\, Pimlico\, London\, SW1V 1EQ\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220607
DTEND;VALUE=DATE:20220610
DTSTAMP:20260515T215236
CREATED:20220207T092209Z
LAST-MODIFIED:20220207T092209Z
UID:33157-1654560000-1654819199@www.pharmajournalist.com
SUMMARY:2nd Annual Gene Therapy Patient Engagement Summit
DESCRIPTION:Integrate the Patient Voice to Develop Safer & More Effective Gene Therapies That Are Meaningful to Patients \n \nAs investment in gene therapies continues to grow rapidly\, more effectively engaging patients throughout development has become a priority for any company serious about building safer and more meaningful gene therapy programs. \nIn this context\, the 2nd Annual Gene Therapy Patient Engagement Summit will unite patient advocacy and engagement leaders from gene therapy and gene editing drug developers\, patient groups and patients themselves to address the specific challenges of genetic therapy patient engagement\, generating actionable insights through detailed case studies and open\, honest discussions. \nJoin us to hear directly from companies and institutions including Spark Therapeutics\, Ultragenyx\, FDA\, Global Genes\, and CRISPR Therapeutics on key topics including managing expectations across gene therapy development\, navigating patient input on one-time transformative treatments with novel clinical trial designs combined with extensive follow-ups\, and developing educational materials on gene therapy to raise awareness in collaboration with patient advocacy organizations. Leverage their knowledge and experiences to ultimately ensure effective creation and implementation of patient-centric gene therapy programs. \nTo know more visit: https://ter.li/c9d6sy
URL:https://www.pharmajournalist.com/event/2nd-annual-gene-therapy-patient-engagement-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220613
DTEND;VALUE=DATE:20220615
DTSTAMP:20260515T215236
CREATED:20220303T102140Z
LAST-MODIFIED:20220303T102140Z
UID:33430-1655078400-1655251199@www.pharmajournalist.com
SUMMARY:Pre Filled Syringes West Coast
DESCRIPTION:SMi’s 6th Annual Conference\nPre-Filled Syringes West Coast\nJune 13 – 14\, 2022 | San Diego\, CA\, USA \nSESSING DEVICE DEVELOPMENT AND REGULATION FOR ADVANCED INNOVATION \nSMi is delighted to announce the 6th annual Pre-Filled Syringes West Coast conference\, to be held in San Diego. As part of SMi’s leading series of drug delivery device conferences\, the 2022 event will provide insights into the rapidly accelerating market of combination product development with industry\, device developer and regulatory perspectives. \n \nThe last year has seen major advances in device design and development with patient usability\, ease of use and safety remaining at the forefront. This upcoming conference will assess the industry movement towards enabling self-administration through advanced device design\, innovations in connectivity to aid the user\, and the increasing importance of biologics and novel drug product considerations for device development. Furthermore\, regulatory bodies and leaders from big pharma will give an international update on the fast-evolving industry landscape. As one of our most sought-after events\, this conference is not to be missed. \nThis two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more. \nBenefits of attending: \n\nDiscover the latest advances in innovative device design for user-centric drug delivery\nAssess evolving approaches to platforms for advanced combination product portfolios\nUncover the key considerations to ensure optimal lifecycle management for drug delivery devices\nExplore how the industry is evolving with global developments including case studies of sustainable practices for drug delivery devices and the industry’s role in mass vaccination campaigns\nEngage in interactive sessions reviewing the landscape of on-body injectors for large volume delivery and the role of connectivity for wearable devices\n\nChAiRs foR 2022: \nTina Rees\, Associate Director\, Human Factors\, Regeneron Pharmaceuticals \nNatalie Abts\, Head of Human Factors Engineering\, Genentech \nFeatured 2022 speakers include:  \n\nSriman Banerjee\, Head of Packaging Development & Commercial Device Engineering\, Takeda\nAmin Sedighiamiri\, Associate Director\, Device Development\, AstraZeneca\nJames Wabby\, Executive Director\, Head of Regulatory Strategy\, Emerging Technologies and Combination Products\, Abbvie\nKhaudeja Bano\, Executive Medical Director\, Combination Product Safety Head\, Amgen\nRachel poker\, Associate Director\, Human Factors\, AstraZeneca\nKristina Li\, Sr. Engineer II\, Technical Development\, Biogen\nsujani Nannapaneni\, Human Factors Principal Research Engineer\, Combination Product Development\, Abbvie\n\nWho should attend? \n\nDrug-delivery developers\nMedical Device Engineers\nPrimary Packaging material designers\nSecondary packagers\nSmart device developers\nTraining device developers\nDevice-safety solution providers\nDrug developers\n\nPrevious attendees include: \nAbbott Laboratories; AbbVie; Advanced Molding Technologies; Aegerion Pharmaceuticals; Ajinomoto Althea\, Inc.; Allergan; Allergen Inc; Almac Group; Amgen; Antares Pharma; Aptar Pharma; AstraZeneca; Baxter Healthcare; BCM Group LLC; BioMarin; Boehringer Ingelheim; Connecticut Spring & Stamping; Credence MedSystems\, Inc.; Execution Metrics\, Inc; Ferring Pharmaceuticals; Fresenius-Kabi; Genentech; Genentech\, Inc.; Gilead Sciences; Glenmark Pharmaceuticals; Harro Hofliger Verpackungsmaschinen GmbH; Inovio Pharmaceuticals; iO Lifesciences; Ionis Pharmaceuticals; Ionis Pharmaceuticals\, Inc.; Matchstick; MedImmune; MedImmune LLC; Medizap; Medtronic; Merck & Co.; Mitsubishi Gas Chemical Company\, Inc; Nemera; Nipro PharmaPackaging; NOVO Engineering\, Inc.; Novo Nordisk; Novo Nordisk A/S; One World DMG; Owen Mumford; Pfenex; Pfenex Inc; Pfizer CentreOne; RAUMEDIC INC; Regeneron; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals\, Inc.; Shire; Smithers Rapra; Steri-Tek; Stevanato Group S.p.A; Subcuject ApS; Suttons Creek Inc; Terumo Corporation; Terumo Medical Corporation; Terumo Pharmaceutical Solutions; UserWise\, Inc.; W. L. Gore & Associates\, Inc.; West Pharmaceutical Services; West Pharmaceutical Services\,; West Pharmaceuticals Services Inc; Worrell; Xeris Pharmaceuticals; ZebraSCI; zebrasci inc; ZEON CORPORATION; Zeon Specialty Materials ; Zeon Specialty Materials Inc \nFind out more here: http://www.prefilled-syringes-westcoast.com/ \nSMi Group offer direct access to key decision makers through tailored sponsorship\, exhibitor and delegate packages. For details contact Daniele Moreschi on +44 7498539226  \nAdditional Contact Info:\nT: +44 (0)20 7827 6088\nE: rjones@smi-online.co.uk\nFollow us: @SMiPharm #SMiPFSUSA
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-west-coast-2022/
LOCATION:San Diego\, CA\, USA
ORGANIZER;CN="SMi Events":MAILTO:rjones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220614
DTEND;VALUE=DATE:20220617
DTSTAMP:20260515T215236
CREATED:20220202T094402Z
LAST-MODIFIED:20220202T094440Z
UID:33099-1655164800-1655423999@www.pharmajournalist.com
SUMMARY:2nd HER2-Targeted Therapies Summit
DESCRIPTION:Outcomes for HER2-expressing breast cancer are patients constantly improving; advancements in diagnostics\, trial design and innovative drug design are at an all-time high; complementing the newly accessible HER2 ‘low’ space and wider range of tumor indications; the last year has given us more progress in HER2-targeted therapies than ever before. \nAs such\, the HER2-Targeted Therapies Summit returns for its second year as the only industry-dedicated forum for large pharma\, biotech and academia to unite under one roof to discuss these developments\, gain competitive insights and ultimately turbocharge practice-changing anti-HER2 drugs to patients. \nAs the clinical and commercial opportunity of HER2-targeted therapies becomes apparent\, join us to connect with over 80+ HER2 experts and expand the clinical utility of your pipeline by exploring HER2 as a multi-tumor target. \nView the full agenda now: https://ter.li/kxq80g
URL:https://www.pharmajournalist.com/event/2nd-her2-targeted-therapies-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220614
DTEND;VALUE=DATE:20220617
DTSTAMP:20260515T215236
CREATED:20220207T102442Z
LAST-MODIFIED:20220207T102621Z
UID:33181-1655164800-1655423999@www.pharmajournalist.com
SUMMARY:2nd Tumor Myeloid-Directed Therapies Summit
DESCRIPTION:Returning in 2022\, the 2nd Tumor Myeloid-Directed Therapeutics Summit is the only industry-focused meeting dedicated to unlocking novel therapeutic potential through the myeloid compartment. \nThis is your ultimate forum to identify\, validate\, and clinically progress myeloid targets to expand the oncologists toolkit and realize better responses by engaging myeloid anti-tumor function. \nDesigned for experts working directly on myeloid-directed therapies\, and those in adjacent immuno-oncology fields\, from cell therapy to checkpoint and engager development. \nIf you’re scratching your head in attempt to enhance efficacy in solid tumors and overcome barriers in the microenvironment\, this is your 500-foot view of the intricate pathways\, interactions\, and novel target development in the tumor microenvironment \nDeep-dive into myeloid biology\, guided by 27+ industry Gurus from the likes of Pionyr Therapeutics\, Gilead Sciences\, Merck\, Verseau Therapeutics\, Carisma Therapeutics\, Pfizer and many more \nWith targets such as TREM1 and TREM2 making waves in the clinic\, analysis of CD47 candidates back-translating to next-generation therapies\, and novel dendritic cell candidates such as FTL3 in development\, this 3-day myeloid extravaganza is unmissable for anyone looking to unlock better therapeutic potential through the myeloid compartment. \nTo know more visit: https://ter.li/2067lj
URL:https://www.pharmajournalist.com/event/2nd-tumor-myeloid-directed-therapies-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220620
DTEND;VALUE=DATE:20220622
DTSTAMP:20260515T215236
CREATED:20220307T120117Z
LAST-MODIFIED:20220307T120117Z
UID:33518-1655683200-1655855999@www.pharmajournalist.com
SUMMARY:2nd Inner Ear Disorders Therapeutics Summit
DESCRIPTION:Biotech companies are paving the way to displace the cochlear implant and cater for the huge unmet need in hearing and balance disorders. The field is booming with excitement\, with pharma companies increasing investment into these pipelines in the race to successfully reverse hearing damage. \n \nReturning as an in-person event to Boston\, the 2nd Inner Ear Disorders Therapeutics Summit will unite drug developers focusing on preventative and regenerative approaches targeting the inner ear. \nDebate the clinical applicability of different modalities\, including small molecule\, stem cell and gene therapy; accurately monitor hearing loss progress\, successfully identify new targets\, optimize preclinical models\, discuss combination strategies for drugs and devices and hear the latest clinical updates and novel translatable research of the inner ear. \nJoin over 100 drug developers from the likes of Otonomy\, Sound Pharmaceuticals\, Frequency Therapeutics\, Astellas\, Sensorion\, Decibel Therapeutics and more at this 4-day disease-agnostic\, modality-agnostic event designed specifically for industry-based experts in inner ear disorders to successfully translate their therapeutics into the clinic. \nTo know more visit: https://ter.li/1wvymk
URL:https://www.pharmajournalist.com/event/2nd-inner-ear-disorders-therapeutics-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220621
DTEND;VALUE=DATE:20220624
DTSTAMP:20260515T215236
CREATED:20211018T092448Z
LAST-MODIFIED:20211203T090456Z
UID:31841-1655769600-1656028799@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China 2022
DESCRIPTION:CPhI & P-MEC China is Asia’s leading pharmaceutical show for trading\, knowledge sharing and networking. It spans all industry sectors along the pharmaceutical supply chain and is your one-stop platform to grow business in the 2nd largest pharma market in the world. CPhI & P-MEC China 2022\, with the co-located shows FDF\, bioLIVE\, Pharma Excipients\, NEX and LABWORLD China\, etc. is expected to draw near 3\,000 exhibitors and hundreds and thousands of professionals from the pharmaceutical industry. \nTo know more visit: https://bit.ly/3n5sp8w
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-2022/
LOCATION:SNIEC\, Shanghai\, China
ORGANIZER;CN="Informa Markets":MAILTO:Candice.lau@informa.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220621
DTEND;VALUE=DATE:20220624
DTSTAMP:20260515T215236
CREATED:20220228T114841Z
LAST-MODIFIED:20220228T114841Z
UID:33407-1655769600-1656028799@www.pharmajournalist.com
SUMMARY:7th Microbiome Movement - Drug Development Summit
DESCRIPTION:The 7th Microbiome Movement – Drug Development Summit returns to Boston at a pivotal time. As the microbiome therapeutic space matures\, with more indications being pursued and more companies conducting trials\, the focus of this event – now in its 7th year – is evolving to showcase these new studies. With this progress however comes new challenges\, and we’re excited to once again be uniting over 300 microbiome pioneers to work towards overcoming these challenges and moving the whole industry closer to commercial approval. \nContinuing to unite the most forward-thinking researchers from the biopharmaceutical industry\, our unrivaled program will uncover microbiome functionality and mechanisms\, decipher translation issues and advance clinical development\, overcome the key GMP manufacturing and scale-up challenges\, whilst also discovering and applying microbiome biomarkers for improved clinical outcomes. \nThis event is the most comprehensive forum for microbiome drug developers and the perfect opportunity for the industry to take a collaborative approach to close the clinical gap\, discover the next generation of microbiome-based therapeutics\, and establish new partnerships to accelerate your research. \nTo know more visit: https://bit.ly/3hss4dD
URL:https://www.pharmajournalist.com/event/7th-microbiome-movement-drug-development-summit/
LOCATION:Revere Boston Common\, 200 Stuart St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@microbiome-movement.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220621
DTEND;VALUE=DATE:20220624
DTSTAMP:20260515T215236
CREATED:20220412T093427Z
LAST-MODIFIED:20220412T093427Z
UID:33768-1655769600-1656028799@www.pharmajournalist.com
SUMMARY:Non-Viral RNA Delivery Systems Summit
DESCRIPTION:Built with biopharmaceutical industry insights\, this in-person conference will delve into the latest advancements of non-viral RNA delivery systems such as LNPs\, exosomes and polymers to set the scene for the translation of targeted\, safe and durable delivery systems for RNA therapeutics and vaccines with improved formulation\, distribution and tissue-specificity. \nDon’t miss 20+ pioneering speakers from large pharma\, innovative biotech\, and KOLs of academia who are shaping the landscape of advanced and emerging non-viral RNA delivery systems for the RNA biopharma community worldwide.  \nJoin this meeting to hear cutting-edge science and latest data on: \n\nExpand Therapeutic Applications with Emerging Non-Viral RNA Delivery Systems\nDiscover Novel LNP & Alternative Technologies to Increase Specificity & Efficacy\nLearn About the Latest Improvements of Non-Viral Delivery Systems for the Delivery of a Broad Range of RNA Payloads\nIncrease Tissue Specific & Extrahepatic Delivery through Optimizing Formulation & Design\nDelve into the emerging Engineering\, Formulation & Packaging Methods to Improve Non- Viral RNA Delivery & Stability\n\nJoin 80+ VPs\, Heads and Directors of RNA delivery\, Formulation and Process development for a deep dive into delivery challenges and strategies of non-viral systems to fully unleash the therapeutic opportunities offered by different RNA therapeutics and vaccines. \nTo know more visit: https://ter.li/ai0qwx
URL:https://www.pharmajournalist.com/event/non-viral-rna-delivery-systems-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220627
DTEND;VALUE=DATE:20220630
DTSTAMP:20260515T215236
CREATED:20220407T094504Z
LAST-MODIFIED:20220407T094504Z
UID:33743-1656288000-1656547199@www.pharmajournalist.com
SUMMARY:3rd TCR-based Therapies for Solid Tumors Summit
DESCRIPTION:Are you using TCRs to target solid tumors yet? \nWith Immunocore having achieved commercialization for the first TCR therapy and Adaptimmune hot on their tail\, 2022 is fast becoming the year for TCRs. \nJoin the TCR-based Therapies for Solid Tumors Summit (June 27-29) to gain knowledge to accelerate the clinical development and improve the safety of these game-changing cell therapies. \nFeaturing 24+ expert speakers\, over 80% of whom are new for 2022\, this summit will address the toughest challenges in TCR development\, such as improving TCR discovery and efficacy\, combating the tumor microenvironment\, optimizing target selection and advancing manufacturing\, preclinical and clinical processes. \nJoin leaders in the field\, including Adaptimmune\, Iovance and TScan as they examine methods to prevent cross reactivity\, increase cell fitness and infiltration\, improve therapy safety and ultimately overcome the hurdles holding back these game-changing treatments from patients in need. \nFind out more in the Event Guide: https://ter.li/sa0pnw
URL:https://www.pharmajournalist.com/event/3rd-tcr-based-therapies-for-solid-tumors-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220628
DTEND;VALUE=DATE:20220701
DTSTAMP:20260515T215236
CREATED:20220427T101322Z
LAST-MODIFIED:20220427T101322Z
UID:33919-1656374400-1656633599@www.pharmajournalist.com
SUMMARY:11th Annual HPAPI Summit
DESCRIPTION:Undoubtedly\, the past two years have changed the pharma industry forever; new modalities are dominating pharma pipelines\, drugs are increasing in potency\, and the restrictions around product quality are tighter than ever before. \nIt is integral that the HPAPI community comes together to apply expertise in ensuring operator safety\, alongside product quality\, to the future of hazardous drug production and fully understand this new landscape\, and regulatory environment. Built in collaboration with industry experts\, the HPAPI Summit provides end-to end coverage tackling; development\, commercial manufacturing & tech transfer\, occupational toxicology\, industrial hygiene & EHS\, across small molecules\, large molecules\, drug conjugates & ATMP\, for a holistic approach to bullet-proofing your hazardous drug production. \nWith sessions championed from the likes of Merck\, Bayer\, AstraZeneca\, Takeda and more\, don’t miss this opportunity to reconnect\, reassess and re-enforce your risk management for your potent pipeline and production at the longest standing and largest global summit for highly potent API’s & hazardous drugs. \nSave up to $700 on your event pass when you book before Friday\, May 20. \nGroup discounts of up to 20% are also available when you bring your team! \nTo know more visit: https://ter.li/3csco9
URL:https://www.pharmajournalist.com/event/11th-annual-hpapi-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220706
DTEND;VALUE=DATE:20220708
DTSTAMP:20260515T215236
CREATED:20220126T093554Z
LAST-MODIFIED:20220303T093817Z
UID:32980-1657065600-1657238399@www.pharmajournalist.com
SUMMARY:Microbiome Connect: Europe
DESCRIPTION:The 8th Annual Microbiome Connect: Europe 2022 dedicated to showcasing the leading drug development and consumer product platforms applying live microbial consortia\, engineered microbes\, and microbial-derived metabolites for therapeutic and health applications in patients and consumers. \nAs the first EMA approved microbiome-targeted therapeutics emerge on the horizon\, drug developers will have to opportunity to benchmark their rational drug platforms\, targeting validated pathways in gastrointestinal\, neurological\, metabolic disorders\, as well as oncology-based indications. \nFurthermore\, there will be separate tracks dedicated to developing novel\, clinical-validated product formulations for nutritional\, digestive wellness\, oral and skincare applications. \nJoin the microbiome field to hear from biotechs\, pharma voices\, investment bodies\, consumer product brands and more\, on how to develop robust\, scalable\, and reproducible formulations for microbe-derived/-targeting products entering late-stage investigations and reaching for the market. \nTo know more visit: https://hubs.ly/Q012R7H40
URL:https://www.pharmajournalist.com/event/microbiome-connect-europe/
LOCATION:Amsterdam
ORGANIZER;CN="Kisaco Research":MAILTO:Jessica.Mockler@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220711
DTEND;VALUE=DATE:20220714
DTSTAMP:20260515T215236
CREATED:20220330T093536Z
LAST-MODIFIED:20220623T094708Z
UID:33675-1657497600-1657756799@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy for Neurological Disorders Europe
DESCRIPTION:Accelerating Europe’s Progress in CNS Gene Therapy \nNavigating Europe-Specific Challenges & European Regulators Requirements; Optimizing Preclinical Research in Neurological Models & Revolutionizing Gene Therapy Delivery to CNS Targets in the Clinic \nAs programs advance globally\, the 3rd Annual Gene Therapy for Neurological Disorders Europe meeting is the industry’s definitive forum dedicated to showcasing the European landscape’s progress and specific regulatory challenges as they move from rare neurological disorders to targeting more common diseases including Parkinson’s\, epilepsy and neurodevelopmental disorders. \nReturning as its first in-person meeting\, with brand new speakers and companies joining the conversation\, attend alongside 100 fellow preclinical\, translational\, clinical and commercial gene therapy experts to overcome your translational challenges and improve the delivery of your gene therapy to its CNS target\, and optimize your European strategy as you move from rare to common patient populations. \nTo know more visit: https://ter.li/l4b1t3
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-for-neurological-disorders-europe/
LOCATION:Paris Marriott Charles de Gaulle Airport Hotel\, Zone Hoteliere\, 5 All. du Verger\, Roissy-en-France\, 95700
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220711
DTEND;VALUE=DATE:20220714
DTSTAMP:20260515T215236
CREATED:20220412T094733Z
LAST-MODIFIED:20220412T094733Z
UID:33773-1657497600-1657756799@www.pharmajournalist.com
SUMMARY:Digital Biomarkers and Clinical Measures in Neurology Summit
DESCRIPTION:The Digital Biomarkers & Clinical Measures in Neurology Summit is the definitive industry forum sharing cross-industry insight to transform clinical development with digital data. \nFrom integrating wearable technologies\, smartphone apps\, and speech-based digital biomarkers into remote clinical research to elucidating pathways to clinical validation to establish therapeutic efficacy\, join industry experts from Merck\, Janssen\, GSK\, Sanofi\, Novartis\, Takeda\, Eli Lilly & Company\, Mitsubishi Tanabe Pharma Holdings America and many more to improve patient retention and establish efficacy with richer datasets. \nTo know more visit: https://ter.li/mk4lmh
URL:https://www.pharmajournalist.com/event/digital-biomarkers-and-clinical-measures-in-neurology-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR